-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $139

Benzinga·03/11/2025 14:22:01
Listen to the news
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $145 to $139.